Biovaxys Confirms First Clinical Site For Phase I Ovarian Cancer Vaccine Trial In France

BioVaxys confirms first clinical site for Phase I ovarian cancer vaccine trial in France

Proactive Investors

Biovaxys: May 8th, 2021 is World Ovarian Cancer Day (Ovarian, HPV Anti-Cancer Vaccine)

High Heal Diaries

BioVaxys says bio-manufacturing partner BioElpida completes next phase of BVX-0918 production

Proactive Investors

BioVaxys Technology says Procare Health deal positions it as leading player in US women's healthcare

Proactive Investors

BioVaxys enters critical tumor cell supply agreement with Deaconess Research Institute

Proactive Investors

Dr. du Bois on Study of Secondary Cytoreductive Surgery in Ovarian Cancer

Vaccines Targeting Breast and Ovarian Cancer

Phase II trial of cemiplimab and ISA101b vaccine in HPV16+ cervical cancer

NC410 and pembrolizumab in MSS/MSI-L colorectal (CRC) and ovarian cancer

GOG-0218: which patients with ovarian cancer experience highest benefit from 1L bevacizumab?

Biovaxys (BIOV.C) Founder & CEO James Passin talks about their tech, Covid & cancer treatment (Ep56)

Potential of Genetic Testing Beyond BRCA1/2 in Ovarian Cancer

Impact of hormones on BRCA breast cancer risk

Ovarian Cancer Webinar 15 February 2023 complete

AORTIC Information

The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer

Biomarker-Driven Frontline Ovarian Cancer Treatment

Ovarian Cancer – An Introduction, with Dr. Paul Sabbatini

Phase I dose expansion results of CYT-0851 plus capecitabine in platinum-resistant ovarian cancer

Treatment ovarian cancer with novel targeted therapies and IO